AgomAb Therapeutics NV — insider transactions
7 transactions on record · AGMB · CIK 2020932
Aggregates
computed from the filings belowPurchases, 12m
7
count of open-market buys
Sales, 12m
0
count of open-market sales
Buy / sell ratio, 12m
—
no sales recorded
Distinct insiders, 12m
3
Bought, 3m
$266.7K
Sold, 3m
$0
Median disclosure lag
1.0 d
trade date to filing date
Largest single trade, 24m
$50.9K
2026-10-05
Director share, 12m
57.1%
of transactions where role is stated
Current run
7 buys
consecutive same-direction transactions
Net 3m flow
$266.7K
purchases minus sales
Total on record
7
Transactions
7 most recent shown| Disclosed | Traded | Lag, d | Insider | Role | Transaction | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-07 | 2026-10-06 | 1 | Kemula Pierre Thadee Victor | Chief Financial Officer | Open market purchase | 5,000 | $8.57 | $42.9K | filing |
| 2026-10-07 | 2026-10-06 | 1 | Kemula Pierre Thadee Victor | Chief Financial Officer | Open market purchase | 2,000 | $8.54 | $17.1K | filing |
| 2026-10-07 | 2026-10-05 | 2 | Knotnerus Tim Jasper | Director, Chief Executive Officer | Open market purchase | 6,000 | $8.48 | $50.9K | filing |
| 2026-10-07 | 2026-10-06 | 1 | Knotnerus Tim Jasper | Director, Chief Executive Officer | Open market purchase | 5,000 | $8.70 | $43.5K | filing |
| 2026-10-07 | 2026-10-06 | 1 | Epstein David R | Director | Open market purchase | 5,000 | $8.70 | $43.5K | filing |
| 2026-10-07 | 2026-10-06 | 1 | Kemula Pierre Thadee Victor | Chief Financial Officer | Open market purchase | 3,000 | $8.67 | $26K | filing |
| 2026-10-07 | 2026-10-05 | 2 | Epstein David R | Director | Open market purchase | 5,000 | $8.57 | $42.9K | filing |